Anti-CLL1 CAR-T (Guangzhou Bio-Gene)

抗CLL-1嵌合抗原受体T细胞疗法 (广州百暨基因)

Report date: 2023/11/09 20:00:57

Base Information

Drug NameAnti-CLL1 CAR-T (Guangzhou Bio-Gene)

Drug Alias Name自体抗CLL-1嵌合抗原受体T细胞注射液BG-1805BG1805

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-C-Type lectin domain family 12 member A

TargetsC-Type lectin domain family 12 member A

Therapy Area/IndicationsLeukemia, Myeloid, AcuteLeukemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesGuangzhou Bio-Gene Technology Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Bio-Gene Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, AcuteLeukemia

Inactive IndicationsN/A

Other Information

ATC CodeN/A